Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes.
Sparbier CE, Gillespie A, Gomez J, Kumari N, Motazedian A, Chan KL, Bell CC, Gilan O, Chan YC, Popp S, Gough DJ, Eckersley-Maslin MA, Dawson SJ, Lehner PJ, Sutherland KD, Ernst P, McGeehan GM, Lam EYN, Burr ML, Dawson MA. Sparbier CE, et al. Among authors: mcgeehan gm. Nat Cell Biol. 2023 Feb;25(2):258-272. doi: 10.1038/s41556-022-01056-x. Epub 2023 Jan 12. Nat Cell Biol. 2023. PMID: 36635503 Free PMC article.
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. Issa GC, et al. Among authors: mcgeehan gm. Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15. Nature. 2023. PMID: 36922593 Free PMC article. Clinical Trial.
MEN1 mutations mediate clinical resistance to menin inhibition.
Perner F, Stein EM, Wenge DV, Singh S, Kim J, Apazidis A, Rahnamoun H, Anand D, Marinaccio C, Hatton C, Wen Y, Stone RM, Schaller D, Mowla S, Xiao W, Gamlen HA, Stonestrom AJ, Persaud S, Ener E, Cutler JA, Doench JG, McGeehan GM, Volkamer A, Chodera JD, Nowak RP, Fischer ES, Levine RL, Armstrong SA, Cai SF. Perner F, et al. Among authors: mcgeehan gm. Nature. 2023 Mar;615(7954):913-919. doi: 10.1038/s41586-023-05755-9. Epub 2023 Mar 15. Nature. 2023. PMID: 36922589 Free PMC article. Clinical Trial.
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Fiskus W, et al. Among authors: mcgeehan gm. Blood Cancer J. 2023 Apr 13;13(1):53. doi: 10.1038/s41408-023-00826-6. Blood Cancer J. 2023. PMID: 37055414 Free PMC article.
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Bourgeois W, Cutler JA, Aubrey BJ, Wenge DV, Perner F, Martucci C, Henrich JA, Klega K, Nowak RP, Donovan KA, Boileau M, Wen Y, Hatton C, Apazidis AA, Olsen SN, Kirmani N, Pikman Y, Pollard JA, Perry JA, Sperling AS, Ebert BL, McGeehan GM, Crompton BD, Fischer ES, Armstrong SA. Bourgeois W, et al. Among authors: mcgeehan gm. Blood. 2024 Apr 11;143(15):1513-1527. doi: 10.1182/blood.2023021105. Blood. 2024. PMID: 38096371
The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML.
Rasouli M, Blair H, Troester S, Szoltysek K, Cameron R, Ashtiani M, Krippner-Heidenreich A, Grebien F, McGeehan G, Zwaan CM, Heidenreich O. Rasouli M, et al. Hemasphere. 2023 Jul 27;7(8):e935. doi: 10.1097/HS9.0000000000000935. eCollection 2023 Aug. Hemasphere. 2023. PMID: 37520776 Free PMC article.
Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model.
Carter BZ, Mak PY, Tao W, Ostermann LB, Mak DH, Ke B, Ordentlich P, McGeehan GM, Andreeff M. Carter BZ, et al. Among authors: mcgeehan gm. Haematologica. 2023 Sep 1;108(9):2513-2519. doi: 10.3324/haematol.2022.281927. Haematologica. 2023. PMID: 36727398 Free PMC article. No abstract available.
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.
Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Mill CP, et al. Among authors: mcgeehan gm. Leukemia. 2023 Jun;37(6):1336-1348. doi: 10.1038/s41375-023-01882-4. Epub 2023 Mar 28. Leukemia. 2023. PMID: 36977823 Free PMC article.
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.
Aubrey BJ, Cutler JA, Bourgeois W, Donovan KA, Gu S, Hatton C, Perlee S, Perner F, Rahnamoun H, Theall ACP, Henrich JA, Zhu Q, Nowak RP, Kim YJ, Parvin S, Cremer A, Olsen SN, Eleuteri NA, Pikman Y, McGeehan GM, Stegmaier K, Letai A, Fischer ES, Liu XS, Armstrong SA. Aubrey BJ, et al. Among authors: mcgeehan gm. Nat Cancer. 2022 May;3(5):595-613. doi: 10.1038/s43018-022-00366-1. Epub 2022 May 9. Nat Cancer. 2022. PMID: 35534777 Free PMC article.
49 results